• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?

作者信息

Nordlinger Bernard, Poston Graeme J, Goldberg Richard M

机构信息

Hôpital Ambroise Paré, Boulogne; and Assistance Publique-Hôpitaux de Paris, Université de Versailles, Versailles, France.

Aintree University Hospital; and Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.

出版信息

J Clin Oncol. 2015 Jan 20;33(3):241-3. doi: 10.1200/JCO.2014.58.3989. Epub 2014 Nov 17.

DOI:10.1200/JCO.2014.58.3989
PMID:25403221
Abstract
摘要

相似文献

1
Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?新的EPOC试验结果会改变局限于肝脏的可切除转移性结直肠癌患者的管理实践吗？
J Clin Oncol. 2015 Jan 20;33(3):241-3. doi: 10.1200/JCO.2014.58.3989. Epub 2014 Nov 17.
2
Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.西妥昔单抗缩小肿瘤化疗后转移性结直肠癌的肝切除率：英国回顾性观察研究
Eur J Surg Oncol. 2015 Apr;41(4):499-505. doi: 10.1016/j.ejso.2015.01.032. Epub 2015 Feb 7.
3
Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.美国社区肿瘤医疗实践中根据 Kirsten 大鼠肉瘤病毒癌基因同源物基因型的转移性结直肠癌治疗模式
Clin Colorectal Cancer. 2014 Sep;13(3):178-84. doi: 10.1016/j.clcc.2014.05.001. Epub 2014 Jun 23.
4
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.前瞻性 II 期研究：新辅助 FOLFOX6 加西妥昔单抗治疗结直肠癌和不可切除的肝转移患者。
Cancer Chemother Pharmacol. 2013 Jul;72(1):223-30. doi: 10.1007/s00280-013-2190-1. Epub 2013 May 21.
5
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.KRAS 密码子 12 突变型肿瘤的特定突变对接受西妥昔单抗一线治疗的转移性结直肠癌患者治疗效果的影响：三项试验的汇总分析。
Oncology. 2012;83(5):241-7. doi: 10.1159/000339534. Epub 2012 Aug 29.
6
Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.接受新辅助化疗（包括使用贝伐单抗或西妥昔单抗）的结直肠癌肝转移患者在肝切除术后的组织学反应、肿瘤破坏模式及临床结局。
Eur J Surg Oncol. 2015 Jul;41(7):868-74. doi: 10.1016/j.ejso.2015.03.223. Epub 2015 Mar 24.
7
Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.使用西妥昔单抗联合FOLFIRI或FOLFOX4治疗方案对KRAS野生型转移性结直肠癌患者进行前瞻性分析。
Genet Mol Res. 2011 Oct 3;10(4):3002-12. doi: 10.4238/2011.October.3.4.
8
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.《转移性结直肠癌国际指南的改编：亚洲共识》
Clin Colorectal Cancer. 2014 Sep;13(3):145-55. doi: 10.1016/j.clcc.2014.06.004. Epub 2014 Jun 26.
9
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.西妥昔单抗新辅助化疗后结直肠癌肝转移的肿瘤反应和二次可切除性：CELIM 随机 2 期试验。
Lancet Oncol. 2010 Jan;11(1):38-47. doi: 10.1016/S1470-2045(09)70330-4. Epub 2009 Nov 26.
10
Common side effects and interactions of colorectal cancer therapeutic agents.结直肠癌治疗药物的常见副作用及相互作用。
J Pract Nurs. 2011 Spring;61(1):7-20.

引用本文的文献

1
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases-a phase II study.LM02试验：帕尼单抗与FOLFIRI用于野生型RAS、潜在可切除的结直肠癌肝转移患者的围手术期治疗——一项II期研究。
Front Oncol. 2023 Aug 9;13:1231600. doi: 10.3389/fonc.2023.1231600. eCollection 2023.
2
Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates.结直肠癌肝转移的围手术期全身化疗：最新进展
Cancers (Basel). 2021 Sep 13;13(18):4590. doi: 10.3390/cancers13184590.
3
Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer.
结直肠癌辅助治疗试验的统计学考量
Cancers (Basel). 2020 Nov 19;12(11):3442. doi: 10.3390/cancers12113442.
4
A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial).多中心 II 期临床试验评估 mFOLFOX6+Cetuximab 作为诱导化疗实现局部晚期结直肠癌肝转移患者 R0 切除的疗效（NEXTO 试验）。
Ann Surg Oncol. 2020 Oct;27(11):4188-4195. doi: 10.1245/s10434-020-08627-y. Epub 2020 Jun 8.
5
Emerging Systemic Therapies for Colorectal Cancer.结直肠癌的新兴全身治疗方法
Clin Colon Rectal Surg. 2018 May;31(3):179-191. doi: 10.1055/s-0037-1602238. Epub 2018 Apr 1.
6
Centralization of Liver Cancer Surgery and Impact on Multidisciplinary Teams Working on Stage IV Colorectal Cancer.肝癌手术的集中化及其对从事IV期结直肠癌治疗的多学科团队的影响。
Oncol Rev. 2017 Jul 31;11(2):331. doi: 10.4081/oncol.2017.331. eCollection 2017 Jun 14.
7
Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis?分子生物标志物能否取代可切除结直肠癌肝转移的临床风险评分？
World J Gastrointest Oncol. 2017 Mar 15;9(3):98-104. doi: 10.4251/wjgo.v9.i3.98.
8
Colorectal Liver Metastases: A Critical Review of State of the Art.结直肠癌肝转移：对当前技术水平的批判性综述
Liver Cancer. 2016 Nov;6(1):66-71. doi: 10.1159/000449348. Epub 2016 Nov 29.
9
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.新EPOC研究中的疾病进展模式、进展性疾病的治疗及进展后生存期
Br J Cancer. 2016 Aug 9;115(4):420-4. doi: 10.1038/bjc.2016.208. Epub 2016 Jul 19.
10
Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.术前卡培他滨和奥沙利铂强化放化疗联合或不联合诱导化疗用于局部晚期直肠癌合并同步肝局限性可切除转移患者的II期研究
Am J Clin Oncol. 2016 Dec;39(6):623-629. doi: 10.1097/COC.0000000000000315.